Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.
Advertisement

Related Content

EU Pharma Ups Share Buybacks In 2012
GSK’s Deal With DoJ Is Fourth In Eight Years; Exec Liability Uncertain
No End In Sight: Pharma Companies Continue To Face Government Probes
Acquittal Of Ex-GSK Lawyer Unlikely To Deter Government Prosecution Of Execs
GSK Ups Legal Reserve, May Break Pfizer's Settlement Record
GSK Ups Legal Reserve, May Break Pfizer's Settlement Record
DoJ Case Against GSK Lawyer Flags What Individual Behavior Government May Target
Senate Finance Committee Inquires Into Manufacturer Medicaid Best Price Calculations

Topics

Advertisement
UsernamePublicRestriction

Register

PS073006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel